/ Notícias

SUS incorpora o Pertuzumabe no tratamento do câncer de mama HER2-positivo.

Nestes dias tão difíceis para o país e para a saúde pública uma EXCELENTE NOTÍCIA: a incorporação, pelo SUS, do PERTUZUMABE para tratamento das pacientes com câncer de mama metastático HER2-positivo. Isto representa Mais VIDAS com mais QUALIDADE!!!

Veja a portaria que oficializa o assunto:
http://portal.imprensanacional.gov.br/todas?p_p_id=101&p_p_lifecycle=0&p_p_state=maximized&p_p_mode=view&_101_struts_action={46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}2Fasset_publisher{46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}2Fview_content&_101_returnToFullPageURL=http{46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}3A{46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}2F{46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}2Fportal.imprensanacional.gov.br{46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}2Fweb{46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}2Fguest{46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}2Ftodas{46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}3Fp_auth{46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}3DZCTjlyRH{46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}26p_p_id{46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}3D3{46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}26p_p_lifecycle{46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}3D1{46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}26p_p_state{46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}3Dnormal{46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}26p_p_state_rcv{46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}3D1&_101_assetEntryId=776420&_101_type=content&_101_groupId=68942&_101_urlTitle=portaria-n-57-de-4-de-dezembro-de-2017&inheritRedirect=true